R-Pharm US — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

R-Pharm US is a private, commercial-stage biopharmaceutical company with a focus on oncology and chronic autoimmune diseases. The company has built its portfolio through strategic acquisitions and in-licensing, notably commercializing IXEMPRA® for metastatic breast cancer and episil® for oral mucositis pain. While its original description mentions a discovery platform for novel prodrugs, current public-facing activities emphasize the commercialization of existing specialty medicines and the clinical development of IXEMPRA® in new indications like ovarian cancer. The company operates with a fully integrated model from development to commercialization.

OncologyChronic Immune DiseasesSupportive Care

Technology Platform

Discovery and development of proprietary NME prodrugs designed to improve attributes (e.g., safety, bioavailability, abuse susceptibility) of approved drugs.

Opportunities

Expanding the label of IXEMPRA into platinum-resistant ovarian cancer addresses a high-need population with limited options, offering significant commercial upside.

The supportive care market for oral mucositis, targeted by episil®, is substantial and aligns with the core oncology focus, providing synergistic commercial opportunities.

Risk Factors

Heavy reliance on the commercial success and clinical development of a single core asset (IXEMPRA) creates significant concentration risk.

As a private, fully integrated company, it faces commercial execution risks in the competitive U.S.

market and depends on successful business development to sustain its pipeline.

Competitive Landscape

In metastatic breast cancer, IXEMPRA competes in later-line settings against other chemotherapies and targeted agents. In ovarian cancer, it would enter a competitive landscape with newer PARP inhibitors and angiogenesis inhibitors. episil® competes in the oral mucositis pain management market against other barrier films, mouthwashes, and analgesics.

More companies in Small Molecule Drugs →More companies in United States →